Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 9/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | TAS2R8 | Q9NYW2 | 3/20 | 0.43 |
| ▸ | PARG | Q86W56 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.40 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.40 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18255894 | 0.96 | TRPA1 (0.48) | TRPA1KMT2APARGPOLBHIF1A | |
| SCHEMBL20182687 | 0.84 | TRPA1 (0.44) | TRPA1KMT2APARGPOLBHIF1A | |
| SCHEMBL18256127 | 0.81 | ADORA2B (0.54) | KMT2APOLBRXFP1 | |
| SCHEMBL20182665 | 0.77 | TRPA1 (0.44) | TRPA1KMT2APARGPOLBHIF1A | |
| SCHEMBL18256137 | 0.77 | KMT2A (0.66) | KMT2APOLBRXFP1 | |
| SCHEMBL18256065 | 0.76 | KMT2A (0.64) | KMT2ARXFP1 | |
| SCHEMBL18256106 | 0.76 | TRPA1 (0.44) | TRPA1KMT2APARGPOLBHIF1A | |
| SCHEMBL18256053 | 0.75 | TRPA1 (0.44) | TRPA1KMT2APARGPOLBHIF1A | |
| SCHEMBL18256060 | 0.75 | KMT2A (0.66) | KMT2APOLBRXFP1 | |
| SCHEMBL20205938 | 0.74 | KMT2A (0.48) | TRPA1KMT2APOLBHIF1ARXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10278973-B2 | Hydroxyl purine compounds and use thereof | Guangdong Raynovent Biotech Co., Ltd. (CN) | 2019-05-07 | — | — | US | disclosed |
| US-20180140607-A1 | HYDROXYL PURINE COMPOUNDS AND USE THEREOF | Guangdong Raynovent Biotech Co., Ltd. (CN) | 2018-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180140607-A1 | HYDROXYL PURINE COMPOUNDS AND USE THEREOF | PNP, PDE7A, PDE2A | TRPA1 2926/4885KMT2A 3576/4885TAS2R8 3324/4885 |
| US-10278973-B2 | Hydroxyl purine compounds and use thereof | PNP, PDE7A, PDE2A | TRPA1 2926/4885KMT2A 3576/4885TAS2R8 3324/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.